Nuclear expression of YB-1 in diffuse large B-cell lymphoma: Correlation with disease activity and patient outcome

European Journal of Haematology

Volumn 83, Issue 4, 2009, Pages 313-319

  Xu, Wenling ^a   Zhou, Leilei ^a   Qin, Rujuan ^a   Tang, Huarong ^a   Shen, Huiling ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Diffuse large B cell lymphoma; P glycoprotein; Poor prognosis; Y box binding protein 1

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; PREDNISOLONE; VINCRISTINE; Y BOX BINDING PROTEIN 1;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CELL NUCLEUS; CLINICAL FEATURE; CYTOPLASM; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEGAVOLTAGE RADIOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PROGNOSIS; TREATMENT OUTCOME; Y-BOX-BINDING PROTEIN 1;

EID: 70349118026     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01285.x     Document Type: Article

References (26)

1. The international non-Hodgkin's lymphoma prognostic factor project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 329 : 987 994.
2. Abd El-Hameed A, De Novo. Nodal diffuse large B-cell lymphoma: identification of biologic prognostic factors. J Egypt Natl Canc Inst 2005 17 : 20 8.
3. Wan FS, Velasquez JW, Tucker S, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989 7 : 1518 1527.
4. Pui CH, Ip SH, Kung P, et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987 70 : 624 628.
5. Ristamaki R, Joensuu H, Lappalainen K, et al. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma. Blood 1997 90 : 4039 4045.
6. Zhen H, Shengkan J, Kathleen W. Transcriptional activation of the MDR1 gene by UV irradiation. J Biol Chem 2000 275 : 2979 2985.
7. Oda Y, Ohishi Y, Saito T, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003 199 : 251 258.
8. Huang X, Ushijima K, Komai K. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 2004 93 : 287 291.
9. Fujita T, Ito K, Izumi H, et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 2005 11 : 8837 8844.
10. Hiraoka H, Kimura N, Furukawa Y, et al. Up-regulation of P-glycoprotein expression in small intestine under chronic serotonin-depleted conditions in rats. J Pharmacol Exp Ther 2005 312 : 248 255.
11. Gessner C, Woischwill C, Schumacher A, et al. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir J 2004 23 : 14 9.
12. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971 31 : 1860 1861.
13. Bergmann S, Royer-Pokora B, Fietze E, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005 65 : 4078 4087.
14. Raffetseder U, Frye B, Rauen T, et al. Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. J Biol Chem 2003 278 : 18241 18248.
15. Lasham A, Moloney S, Hale T, et al. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem 2003 278 : 35516 35523.
16. Bader AG, Vot PK. Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol 2005 25 : 2095 2106.
17. Yoshimatsu T, Uramoto H, Oyama T, et al. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer. Anticancer Res 2005 25 : 3437 3443.
18. Materna V, Pleger J, Hoffmann U, et al. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004 94 : 152 160.
19. Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005 68 : 422 431.
20. Bargou RC, Jürchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997 4 : 378 380.
21. Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999 85 : 2450 2454.
22. Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996 56 : 4224 4228.
23. Oda Y, Sakamoto A, Shinohara N, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998 4 : 2273 2277.
24. Tsujimura S, Saito K, Nakayama S, et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 2004 9 : 1265 1273.
25. Janz M, Harbeck N, Dettemar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002 97 : 278 282.
26. Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998 25 : 483 491.